Synuclein-alpha(Phospho Tyr136) Polyclonal Antibody

Alpha-synuclein is a member of the synuclein family, which also includes beta- and gamma-synuclein. Synucleins are abundantly expressed in the brain and alpha- and beta-synuclein inhibit phospholipase D2 selectively. SNCA may serve to integrate presynaptic signaling and membrane trafficking. Defects in SNCA have been implicated in the pathogenesis of Parkinson disease. SNCA peptides are a major component of amyloid plaques in the brains of patients with Alzheimer's disease. Alternatively spliced transcripts encoding different isoforms have been identified for this gene.

Introducing the SYNUCLEIN-ALPHA(PHOSPHO TYR136) POLYCLONAL ANTIBODY, a cutting-edge product designed to revolutionize the field of molecular biology. This meticulously crafted antibody is specifically engineered to target the phosphorylated tyrosine 136 residue of the synuclein-alpha protein, offering unparalleled accuracy and sensitivity in detecting and quantifying this crucial biomarker.

With its polyclonal nature, this antibody exhibits exceptional affinity and specificity, ensuring reliable and reproducible results in a wide range of applications. Its superior performance is further enhanced by its exceptional stability and long shelf life, guaranteeing consistent and reliable performance over extended periods.

The SYNUCLEIN-ALPHA(PHOSPHO TYR136) POLYCLONAL ANTIBODY is meticulously manufactured using state-of-the-art techniques and stringent quality control measures. Each batch undergoes rigorous testing to ensure optimal performance, providing researchers with the utmost confidence in their experimental outcomes.

This groundbreaking antibody opens up new avenues for research in neurodegenerative diseases, particularly Parkinson's disease, where synuclein-alpha has been implicated as a key player. By targeting the phosphorylated tyrosine 136 residue, this antibody enables precise investigation of the role of synuclein-alpha in disease progression, offering invaluable insights into potential therapeutic interventions.

The SYNUCLEIN-ALPHA(PHOSPHO TYR136) POLYCLONAL ANTIBODY is compatible with a variety of techniques, including Western blotting, immunohistochemistry, and immunofluorescence, allowing for versatile and comprehensive analysis. Its exceptional sensitivity enables detection of even low-abundance synuclein-alpha species, facilitating accurate quantification and characterization.

In summary, the SYNUCLEIN-ALPHA(PHOSPHO TYR136) POLYCLONAL ANTIBODY represents a breakthrough in molecular biology research, providing researchers with a powerful tool to unravel the complexities of synuclein-alpha and its involvement in neurodegenerative diseases. With its unrivaled specificity, stability, and versatility, this antibody is poised to drive scientific advancements and pave the way for novel therapeutic strategies.